Skip to content
Head to head

Regeneron Pharmaceuticals vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: REGN · VRTX

Updated 5 minutes ago

1-year performance, rebased to 100

REGN +31.4%VRTX +18.7%
Regeneron Pharmaceuticals edges it on the scoreable measures. Regeneron Pharmaceuticals has the highest Quant Rating (77); Regeneron Pharmaceuticals has done best over the past year (+25%); Regeneron Pharmaceuticals trades cheapest on trailing earnings.
REGNVRTX
Snapshot
Sector--Biotechnology
Last price920.69515.02
Change today-0.19%-1.08%
1-year return+25.4%+22.0%
Market cap$95.24B$130.58B
52-week range590.23 – 990.72412.27 – 568.67
Valuation
P/E (TTM)20.3533.14
P/E percentile, own 5-yr range74th99th
P/B2.846.25
Dividend yield0.40%0.00%
Profitability & growth
EPS (TTM)41.4815.32
Net profit (TTM)$4.29B$3.88B
Revenue (TTM)$16.90B$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+36.3%+11.8%
Gross margin85.8%85.5%
Operating margin30.4%33.1%
Net margin28.5%30.7%
Free cash flow (TTM)$3.63B$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership90.9%96.8%
Insider activity (12mo)18 buy / 32 sell28 buy / 22 sell
Short interest (% of float)2.2%1.9%
Analyst consensus70% buy / 30% hold (23)95% buy / 5% hold (21)
Analyst price target$966 (+5%)$624 (+21%)
StockVane view
StockVane Quant RatingC (77)C (68)
Company
Employees15,4106,400
Founded19881989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.